These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27788856)

  • 1. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials.
    Pocock SJ; Bakris G; Bhatt DL; Brar S; Fahy M; Gersh BJ
    J Am Coll Cardiol; 2016 Nov; 68(18):2016-2025. PubMed ID: 27788856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente].
    Azpiri-López JR; Assad-Morell JL; Ponce de León-Martínez E; Monreal-Puente R; Dávila-Bortoni A; Vázquez-Díaz LA; Treviño-Frutos RJ; Barrera-Oranday F; Del Angel-Soto JG; Martínez JG; Arellano-Torres M
    Arch Cardiol Mex; 2015; 85(2):154-7. PubMed ID: 25700579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
    Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.
    Esler MD; Krum H; Schlaich M; Schmieder RE; Böhm M; Sobotka PA;
    Circulation; 2012 Dec; 126(25):2976-82. PubMed ID: 23248063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension.
    Böhm M; Tsioufis K; Kandzari DE; Kario K; Weber MA; Schmieder RE; Townsend RR; Kulenthiran S; Ukena C; Pocock S; Ewen S; Weil J; Fahy M; Mahfoud F
    J Am Coll Cardiol; 2021 Sep; 78(10):1028-1038. PubMed ID: 34474735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of renal denervation for resistant hypertension.
    Bhatt DL; Kandzari DE; O'Neill WW; D'Agostino R; Flack JM; Katzen BT; Leon MB; Liu M; Mauri L; Negoita M; Cohen SA; Oparil S; Rocha-Singh K; Townsend RR; Bakris GL;
    N Engl J Med; 2014 Apr; 370(15):1393-401. PubMed ID: 24678939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.
    Desch S; Okon T; Heinemann D; Kulle K; Röhnert K; Sonnabend M; Petzold M; Müller U; Schuler G; Eitel I; Thiele H; Lurz P
    Hypertension; 2015 Jun; 65(6):1202-8. PubMed ID: 25824248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.
    Azizi M; Schmieder RE; Mahfoud F; Weber MA; Daemen J; Davies J; Basile J; Kirtane AJ; Wang Y; Lobo MD; Saxena M; Feyz L; Rader F; Lurz P; Sayer J; Sapoval M; Levy T; Sanghvi K; Abraham J; Sharp ASP; Fisher NDL; Bloch MJ; Reeve-Stoffer H; Coleman L; Mullin C; Mauri L;
    Lancet; 2018 Jun; 391(10137):2335-2345. PubMed ID: 29803590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension　- Insights From the SYMPLICITY HTN-3 Trial.
    Kario K; Bhatt DL; Kandzari DE; Brar S; Flack JM; Gilbert C; Oparil S; Robbins M; Townsend RR; Bakris G
    Circ J; 2016 May; 80(6):1404-12. PubMed ID: 27118620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation?
    Epstein M; de Marchena E
    J Am Soc Hypertens; 2015 Feb; 9(2):140-9. PubMed ID: 25649995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.
    Böhm M; Kario K; Kandzari DE; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Konstantinidis D; Choi JW; East C; Lee DP; Ma A; Ewen S; Cohen DL; Wilensky R; Devireddy CM; Lea J; Schmid A; Weil J; Agdirlioglu T; Reedus D; Jefferson BK; Reyes D; D'Souza R; Sharp ASP; Sharif F; Fahy M; DeBruin V; Cohen SA; Brar S; Townsend RR;
    Lancet; 2020 May; 395(10234):1444-1451. PubMed ID: 32234534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    ; Esler MD; Krum H; Sobotka PA; Schlaich MP; Schmieder RE; Böhm M
    Lancet; 2010 Dec; 376(9756):1903-9. PubMed ID: 21093036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal denervation: current state and future perspectives].
    Kara K; Bruck H; Kahlert P; Plicht B; Mahabadi AA; Konorza T; Erbel R
    Herz; 2012 Nov; 37(7):746-53. PubMed ID: 23073661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation.
    Patel HC; Hayward C; Ozdemir BA; Rosen SD; Krum H; Lyon AR; Francis DP; di Mario C
    Hypertension; 2015 Feb; 65(2):401-6. PubMed ID: 25403604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M
    J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.